Print Print   Email Email   Share Share
Stock price graph
     

"Our goal is to create long-term fundamental value for our shareholders by advancing the mission of PolyMedix through development of our product pipeline."

Corporate Presentation
PolyMedix Corporate Presentation

View all »   RSSRecent Releases

May 10, 2012
PolyMedix Provides Update on PMX-60056 Program

Apr 23, 2012
PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic

Apr 20, 2012
PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic

Apr 10, 2012
PolyMedix Restructures Its Debt and Secures $12 Million Credit Facility

Apr 2, 2012
PolyMedix's PMX-30063 First in Class Defensin-Mimetic Antibiotic Demonstrates Activity Against Drug-Resistant Bacterial Pathogens

View all »Events & Presentations

Jun 1–5, 2012
American Society of Clinical Oncology

Jun 18–21, 2012
2012 Bio International Convention


IR Contact

Lisa Caperelli
Director, Investor Relations & Corporate Communications

484-598-2406
Email Lisa »

Stock Quote (BB: PYMX)
Price:
0.34
Change:
+ 0.01
Day High:
0.35
Day Low:
0.32
Volume:
334,100
3:28 PM ET on May 17, 2012
Delayed ~20 min. By eSignal.
Website by Graphic Success